Case Series of Patients With Laboratory-Confirmed Marburg Virus Disease in 2023 in Equatorial Guinea
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf208 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Florentino Abaga Ondo Ndoho und 30 weiteren Autor:innen. Beteiligte Einrichtung: Dirección General de Salud Pública, Prevention Sanitaria, Medicina Tradicional y Natural, Ministerio de Sanidad y Bienestar Social de Guinea Ecuatori…. Hauptthemen laut MEDLINE: Marburg Virus Disease, Marburgvirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: World Health Organization.
Abstract (Originalsprache)
Background
Marburg virus disease (MVD) is a severe viral infection caused by the Marburg marburgvirus species. In February 2023, Equatorial Guinea declared its first outbreak. This case series describes the natural history of MVD in 5 patients with laboratory-confirmed disease.
Methods
Patients with confirmed MVD who were admitted to the national treatment center in Bata, Equatorial Guinea were monitored for vital signs and symptoms. Comprehensive clinical data were collected to understand the progression and outcome of the disease.
Results
Five patients were confirmed to have MVD. Three male healthcare workers received a diagnosis diagnosed early in their disease and subsequently survived. The other 2 patients, both female, were admitted later in their disease progression and died within 24 hours of admission. Four patients received remdesivir under a protocol for the monitored emergency use of unregistered and experimental interventions. The early symptoms were nonspecific, with rapid progression to more severe conditions in the later stages of the disease. Early treatment with remdesivir showed the drug to be well tolerated.
Conclusions
Contrary to some reports and the recommended case definition for MVD, our patients presented with a rash but did not exhibit vomiting or diarrhea. Hemorrhagic signs were solely observed in the terminal stage, preceding demise. Despite the limited sample size, these findings emphasize the importance of tailoring the case definition to the specific outbreak. Further evidence on the efficacy and safety of therapeutics for MVD, including remdesivir, should be gathered through well-designed trials during future epidemic responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dirección General de Salud Pública, Prevention Sanitaria, Medicina Tradicional y Natural, Ministerio de Sanidad y Bienestar Social de Guinea Ecuatorial (MINSABS), Malabo, Equatorial Guinea.
- Health Emergencies Programme, World Health Organization (WHO), Genève, Switzerland.
- Dirección General de Coordinación Hospitalaria y Enfermedades Crónicas no Transmisibles, Ministerio de Sanidad y Bienestar Social de Guinea Ecuatorial (MINSABS), Malabo, Equatorial Guinea.
- Hospital Regional de Bata, Ministerio de Sanidad y Bienestar Social de Guinea Ecuatorial (MINSABS), Malabo, Equatorial Guinea.
- Baney Research Laboratory, Ministerio de Sanidad y Bienestar Social Guinea Ecuatorial, Malabo, Equatorial Guinea.
- Centro Médico La Paz, Ministerio de Sanidad y Bienestar Social de Guinea Ecuatorial (MINSABS), Malabo, Equatorial Guinea.
ORCID-Profile: Luca Fontana, Candido Ondo Ondo Avomo, Ladislao Ekiri Ngomo Mikue, Domitila Ñadang Fuga Eyemam, Ruggero Giuliani, Frédérique Jacquerioz, Hans-Joerg Lang, Richard Kojan, Stephanie Ngai, Olivier le Polain de Waroux, Anna Silenzi, Michele Di Marco, Anaïs Legand, Maria E Negron, John D Klena, Mary J Choi, Oren Mayer, Florine E M Scholte
Förderung
- World Health Organization
Zitieren
APA
Ondo Ndoho, F. A., Fontana, L., Ondo Avomo, C. O., Mikue, L. E. N., Fuga Eyemam, D. Ñ., Nguere, M. A., Mometolo, I. E., Bibang Nzang, R. N., Nguema Maye, D. M., Hernandez Suarez, Y., Esono, S. E., Miko Ayang, J. A., Giuliani, R., Jacquerioz, F., Lang, H. J., Kojan, R., Chaillon, A., Ngai, S., de Waroux, O. L. P., …, & Diaz, J. (2025). Case Series of Patients With Laboratory-Confirmed Marburg Virus Disease in 2023 in Equatorial Guinea. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf208
Vancouver
Ondo Ndoho FA, Fontana L, Ondo Avomo CO, Mikue LEN, Fuga Eyemam DÑ, Nguere MA, et al. Case Series of Patients With Laboratory-Confirmed Marburg Virus Disease in 2023 in Equatorial Guinea. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf208
BibTeX
@article{OndoNdoho2025,
author = {Ondo Ndoho, Florentino Abaga and Fontana, Luca and Ondo Avomo, Candido Ondo and Mikue, Ladislao Ekiri Ngomo and Fuga Eyemam, Domitila Ñadang and Nguere, Micaela Ayang and Mometolo, Ilda Elobe and Bibang Nzang, Rosalia Nazang and Nguema Maye, Damaso Mitogo and Hernandez Suarez, Yosbanis and Esono, Salvador Eduardo and Miko Ayang, José Antonio and Giuliani, Ruggero and Jacquerioz, Frédérique and Lang, Hans-Joerg and Kojan, Richard and Chaillon, Antoine and Ngai, Stephanie and de Waroux, Olivier le Polain and Silenzi, Anna and Di Marco, Michele and Legand, Anaïs and Formenty, Pierre and Negron, Maria E and Klena, John D and Choi, Mary J and Mayer, Oren and Scholte, Florine E M and Welch, Stephen R and Gutierrez, Emily Zielinski and Diaz, Janet},
title = {Case Series of Patients With Laboratory-Confirmed Marburg Virus Disease in 2023 in Equatorial Guinea},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf208}
}
EUVIMED